Physician profile
Ragaa Iskarous
NPI 1215035274
$3,633.53
in general payments reported to CMS, 2019-2025
29 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $636 · 2021: $655 · 2022: $569 · 2023: $299 · 2024: $374 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.51 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $502.57 | 2019-2025 | Evenity, Otezla, Repatha |
| Amarin Pharma, INC. | $307.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.83 | 2021-2024 | Jardiance |
| Abbvie INC. | $257.91 | 2020-2023 | |
| Lilly USA, LLC | $250.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $233.29 | 2019-2022 | |
| Pfizer INC. | $184.25 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.10 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $121.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.86 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $80.09 | 2019-2020 | |
| Dexcom, INC. | $73.66 | 2021-2022 | |
| Shield Therapeutics INC | $61.00 | 2023 | Accrufer |
| Allergan, INC. | $59.00 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.37 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $55.10 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $54.12 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $53.22 | 2019-2022 | |
| Radius Health, INC. | $49.31 | 2021-2022 | |
| Lundbeck LLC | $45.69 | 2024 | Rexulti |
| Merz North America, INC. | $28.96 | 2025 | |
| Avanir Pharmaceuticals, INC. | $21.27 | 2022 | |
| Glaxosmithkline, LLC. | $20.44 | 2020 | |
| Horizon Therapeutics Plc | $19.36 | 2020 | |
| Phadia US INC. | $19.32 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.12 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.96 | 2025 | Lifevest |
| Redhill Biopharma INC. | $17.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ragaa Iskarous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.